Genotyping Market (By Product: Instruments, Reagents & Kits, Software and Services, Genotyping Services; By Application: Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others; By Technology: PCR, Capillary Electrophoresis, Microarrays, Sequencing, Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-TOF) Mass Spectroscopy, Others; By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033


The global genotyping market size accounted for USD 19.41 billion in 2023 and it is expected to surpass around USD 75.60 billion by 2033, growing at a CAGR of 14.53% during the forecast period 2024 to 2033.

Genotyping Market Size 2024 to 2033

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Key Takeaways

  • North America contributed more than 40.13% of revenue share in 2023.
  • Europe region is expected to expand at the fastest CAGR from 2024 to 2033.
  • By Product, the reagents & kits segment generated more than 62% of the revenue share in 2023.
  • By Application, the pharmacogenomics segment is predicted to dominate the market from 2024 to 2033.
  • By Application, the diagnostics and personalized medicine segment is expected to expand at the fastest CAGR between 2024 and 2033.
  • By Technology, the PCR segment is predicted to grow at a remarkable CAGR of 12% from 2024 to 2033.
  • By End User, the diagnostics and research laboratories segment accounted for more than 37.60% of revenue share in 2023.

Genotyping Market Size in U.S. 2024 to 2033

The U.S. genotyping market size was estimated at USD 5.46 billion in 2023 and is projected to surpass around USD 22.38 billion by 2033 at a CAGR of 15.11% from 2024 to 2033.

U.S. Genotyping Market Size 2024 to 2033

North America accounted for the largest market share in 2023. The region is expected to maintain its dominance owing to the advancements in the healthcare infrastructure, the presence of prominent market players such as Illumina Inc., Thermo Fisher Scientific Inc. Agilent Technologies, and others, growing adoption of technologically advanced products, increasing government funding, and rising prevalence of chronic diseases in the region. For instance, As per the National Center for Chronic Disease Prevention and Health Promotion, 6 out of 10 Americans live with at least one chronic disease. Genotyping techniques are used for the early diagnosis and treatment of chronic disorders.

On the other hand, the Europe market is expected to grow at a significant CAGR during the forecast period due to the rapid growth of the pharma and biopharma companies, technological advancements, and an increase in research and development activities in the region. Furthermore, the Asia Pacific market is projected to register a considerable CAGR during the forecast period owing to the increase in government investment, increasing research projects, and the rise in the number of clinical trials being performed in the region.

Genotyping Market Share, By Region, 2023 (%)

Genotyping Market Overview

The global genotyping market revolves around the product, services and technologies associated with genotyping. Services and products offered by the global genotyping market are further used in multiple fields, including medical research, drug development, agriculture and consumer genetic testing.

Genotype is the heritable information that is carried by all living organisms. Genotyping allows the identification of genetic variants.  Genotyping refers to the technology that helps detect small genetic differences which lead to major changes in phenotype, it includes both physical differences that make us different as well as pathological changes. By comparing a DNA sequence to that of another sample or a reference sequence, genotyping detects variations in genetic complement. It identifies minor changes in genetic sequence within populations such as SNPs. SNPs are single base-pair variations in DNA that occur at particular areas in the genome.

Made up of double helix structure, the human genome carries nucleotide base pairs. They can explain features such as eye colour and inherited diseases like cystic fibrosis and sickle cell anaemia, as well as serve as indicators of risk of developing complex common diseases such as Alzheimer's disease and diabetes. By forecasting an individual's risk of contracting specific diseases or developing targeted therapies based on the genetics of the disease, SNP genotyping can speed up the era of personalized medicine. As Single-nucleotide polymorphisms (SNPs) are also linked with individual therapeutic responses, SNP-based assays may be useful in determining the most appropriate course of treatment.

Growth Factors

The global genotyping market is expected to witness a notable growth during the forecast period owing to the rising research and development activities on personalized medicines. The advancements in tools, software, analysis procedures, rising population, improving research and development (R&D) sector are a few factors that are accelerating the growth of global genotyping market.

The growth of the genotyping market is driven by the use of genotyping in drug development, the launch of novel technologies for reducing errors significantly, the increasing prevalence of target diseases, such as diabetes, cancer, and Alzheimer’s, increase in government funding, the increasing geriatric population, increase in government funding, reducing prices of DNA sequencing, growing importance of genotyping in drug discovery the increase in healthcare expenditure, and the rising genotype research and development activities. Additionally, the market has grown as a result of the increasing frequency of genetic disorders and increasing awareness of personalized medicine.

Report Scope of the Genotyping Market

Report Coverage Detail
Growth Rate from 2024 to 2033 CAGR of 14.53%
Market Size in 2023 USD 19.41 Billion
Market Size by 2033 USD 75.60 Billion
Largest Market North America
Base Year 2023
Forecast Period 2024 To 2033
Segments Covered By Product, By Application, By Technology, and By End User
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Genotyping Market Dynamics

Driver:

Decreasing prices of DNA sequencing due to technological developments

Advancements in technology such as next-generation sequencing (NGS) has reduced the entire costs of DNA sequencing and lowered the overall cost of genomic and genotyping projects. Technological improvements have enabled miniaturization, automation and helped in decreasing the overall total costs. Such technological advancements have boosted the chances of accuracy in sequencing along with the boosted speed in the sequencing procedures.

These factors have expanded the uses of DNA sequencing and permitted clinicians to focus on decision making processes such as choosing and prioritizing therapeutic targets through several genotyping studies. It has also increased the use of sequencing, PCR, capillary electrophoresis, and microarrays in areas such as clinical research and drug development.

Restraints:

High-cost equipment for genotyping is restraining the market growth

The high cost of genotyping is expected to restrain the genotyping market growth. Genotyping equipment is expensive as it has advanced features. The installation and maintenance costs of this equipment are considerably high. As a result, advanced technology such as NGS technology has slowed adoption in many middle and lower-income countries.

Opportunities:

Increasing government support in genotyping research

The rising government support in genotyping research is expected to offer a set of opportunities for the global genotyping market. Several governments across the globe are focused on implementing numerous initiatives to support research institutions that focus on personalized medicine. For instance, in September 2018, the National Institutes of Health granted $28.6 million to the ‘All of Us Research Program’ for the establishment of three genome centers across the United States which will be dedicated to precision medicine research.

Furthermore, the strategic initiatives undertaken by prominent players are expected to accelerate the market’s growth. For instance, in September 2022, a leader in DNA sequencing technologies, Illumina announced the launch of the NovaSeq X Series, new production-scale sequencers. The recent launch platform from Illumina aims to boost the limits of genomic medicine by making it faster, more sustainable, and more powerful. This new technology by the company can generate more than 20,000 genomes per year.

Product Insights

On the basis of products & services, the global genotyping market is segmented into instruments, reagents & kits, software & services, and genotyping services. The reagents & kits segment is expected to expand at a robust growth rate during the forecast period owing to the rising increasing genotyping testing, increasing R&D investments, and increasing adoption of reagents & kits for genotyping in pharmaceuticals and diagnostic centers. On the other hand, the software & services segment is projected to expand at a rapid rate due extensive adoption of software-based services by academic and research institutions.

Application Insights

Based on the application, the global genotyping market is segmented into pharmacogenomics, diagnostics and personalized medicine, agricultural biotechnology, animal genetics, and others. The pharmacogenomics segment is expected to dominate the market over the forecast period. Pharmacogenomics is an example of the field of precision medicine, which tends to customize treatment to an individual person or to a group of people. Pharmacogenomics examines how the individual’s DNA affects and how the individual reacts to drugs. Pharmacogenomics can help an individual to know in advance whether a drug is beneficial and safe for an individual to take or not. In addition, prominent market players are offering solutions for pharmacogenomics studies.

On the other hand, the diagnostics and personalized medicine segment is growing at a significant CAGR during the forecast period due to the wide adoption of genotyping products for research activities and the rising demand for the diagnosis of genetic disorders. Personalized medicine involves the combination of molecular, genetic, and environmental variability in the existing method for the proper management of disorders or illnesses.

Technology Insights

Based on the technology, the global genotyping market is segmented into Polymerase Chain Reaction (PCR), capillary electrophoresis, microarrays, sequencing, matrix-assisted laser desorption/ionization-time of flight (Maldi-TOF) mass spectroscopy, and others. The Polymerase Chain Reaction (PCR) segment is expected to grow at a significant rate during the forecast period owing to the increasing number of CROs, growing demand for advanced diagnostic techniques, and growing prevalence of genetic disorders. Genotyping allows researchers to examine large structural variations in DNA to small genetic changes in DNA like single nucleotide polymorphisms (SNPs). Real-time PCR offers a high throughput solution for genotyping using molecular probes for rapid and accurate results.

On the other hand, the sequencing segment is anticipated to expand at a rapid rate owing to its ability to detect low expression & differentially expressed genes than any other methods. Genotyping by sequencing is a genetic screening method for discovering SNPs and performing genotyping studies.

End User Insights

Based on the end user, the global genotyping market is segmented into pharmaceutical and biopharmaceutical companies, diagnostics and research laboratories, academic institutes, and others. The diagnostics and research laboratories segment is expected to capture a significant market share over the forecast period due to the increasing use of genotyping products for research, the growing demand for the diagnosis of genetic disorders, and the increasing incidence of cancer rises the demand for diagnostic tests are projected to boost the market.

Genotyping Market Share, By End Users, 2023 (%)

On the other hand, the biopharmaceutical and pharmaceutical companies segment is expected to expand at a robust growth rate in the coming years owing to the increasing number of biopharmaceutical and pharmaceutical companies. Companies actively use pharmacogenomics to develop innovative drugs. The increasing need for pharmacogenomics in the drug development process and FDA suggestions to include pharmacogenomics studies and genotyping in the drug discovery process. 

Recent Developments

  • In January 2020, Illumina and Roche announced a partnership to widen patient access to genomic testing. Illumina, Inc., a prominent company in DNA sequencing and other associated technologies and Roche, a leader in diagnostic and pharmaceutical services announced a collaboration to strengthen the adoption of distributable NGS testing, especially for oncology sector. The agreement is expected to bring together capabilities of the company to widen the adoption of next generation sequencing in cancer care.
  • In February 2022, a prominent player in bioanalytical testing and diagnostic testing, Eurofins Scientific announced that one of its subsidiaries, Eurofins Clinical Testing Lu Sarl will be acquiring Genetic Testing Service JSC, which is a leader in genetic testing. Under the acquisition, the company aims to strengthen Eurofins’ business in Asia region while complimenting its global network of clinical diagnostic laboratories.
  • In January 2022, Illumina, Inc announced that the company has entered into a co-development agreement with SomaLogic in order to being SomaScan Proteomics Assay into Illumina’s rapidly growing NGS platform. Under the collaboration, the companies aim to speed up the rapidly growing high throughput sector of proteomics industry. With this step of speeding up Illumina’s NGS technology, researchers can make biological connections from genetic sequence to directly cellular function which aims to grow opportunities for clinical impact.

Genotyping Market Companies

  • Illumina Inc
  • Thermo Fisher Scientific Inc.
  • Qiagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fluidigm Corporation
  • Danaher Corporation
  • Agilent Technologies
  • Eurofins Scientific Inc.
  • GE Healthcare Inc.
  • Bio-Rad Laboratories Inc.
  • Pacific Biosciences of California

Segments Covered in the Report:

By Product

  • Instruments
  • Sequencers & Amplifiers
  • Analyzers
  • Reagents & Kits
  • Software and Services
  • Genotyping Services

By Application

  • Pharmacogenomics
  • Diagnostics and Personalized Medicine
  • Agricultural Biotechnology
  • Animal Genetics
  • Others

By Technology

  • PCR
    • Real-time PCR
    • Digital PCR
  • Capillary Electrophoresis
    • Amplified Fragment Length Polymorphism
    • Restriction Fragment Length Polymorphism
    • Single-Strand Conformation Polymorphism
  • Microarrays
    • DNA Microarrays
    • Peptide Microarrays
    • Others
  • Sequencing
    • Next Generation Sequencing
    • Pyro Sequencing
    • Sanger Sequencing
  • Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-TOF) Mass Spectroscopy
  • Others

By End User

  • Pharmaceutical And Biopharmaceutical Companies
  • Diagnostics And Research Laboratories
  • Academic Institutes
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

What is the genotyping market size?
The global genotyping market size is expected to increase USD 75.60 billion by 2033 from USD 19.41 billion in 2023.
What will be the CAGR of global genotyping market?
The global genotyping market will register growth rate of 14.53% between 2024 and 2033.
Who are the prominent players operating in the genotyping market?
The major players operating in the genotyping market are Illumina Inc, Thermo Fisher Scientific Inc., Qiagen Inc., F. Hoffmann-La Roche Ltd., Fluidigm Corporation, Danaher Corporation, Agilent Technologies, Eurofins Scientific Inc., GE Healthcare Inc., Bio-Rad Laboratories Inc., Pacific Biosciences of California, and Others.
Which are the driving factors of the genotyping market?
The driving factors of the genotyping market are the rising prevalence of target diseases, rising R&D expenditure for precision medicine research, increasing investment by government and pharma & biotechnology firms, and rising demand for genotyping of animal & plant livestock.
Which region will lead the global genotyping market?
North America region will lead the global genotyping market during the forecast period 2024 to 2033.

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample